hemophilia

Sangamo Stock Soars on Positive Hemophilia Treatment Trial
Sangamo Stock Soars on Positive Hemophilia Treatment Trial
TheStreet.com
Sangamo BioSciences
Pfizer
SB-525
hemophilia
clinical trials
Flag link:
IP trouble defers launch of Novo's long-acting hemophilia therapy
IP trouble defers launch of Novo's long-acting hemophilia therapy
Endpoints
Novo Nordisk
Eseproct
hemophilia
Roche
Hemlibra
Flag link:
FDA hemophilia meeting to discuss new efficacy endpoints
FDA hemophilia meeting to discuss new efficacy endpoints
BioCentury
FDA
clinical trials
hemophilia
Flag link:
Genentech and Hemophilia Patients Eye Oct. 4 for Hemlibra Ruling
Genentech and Hemophilia Patients Eye Oct. 4 for Hemlibra Ruling
BioSpace
FDA
Genentech
Hemlibra
hemophilia
Flag link:
Catalyst gives positive hemophilia update as 2 more subjects complete study
Catalyst gives positive hemophilia update as 2 more subjects complete study
Biopharma Dive
Catalyst Bioscences
hemophilia
clinical trials
Flag link:
What's Next for Spark Therapeutics
What's Next for Spark Therapeutics
Motley Fool
Spark Therapeutics
hemophilia
SPK-8011
Flag link:
A bad week for these two biotechs
A bad week for these two biotechs
Motley Fool
Anika Therapeutics
CINGAL
Catalyst Biosciences
CB 2679d
hemophilia
Flag link:
FDA plans to speed path to approval for some gene therapies, starting with hemophilia
FDA plans to speed path to approval for some gene therapies, starting with hemophilia
Stat
FDA
drug approvals
gene therapies
Scott Gottlieb
hemophilia
Flag link:
Roche flags first case of anti-drug antibodies that forced a patient to drop would-be blockbuster Hemlibra
Roche flags first case of anti-drug antibodies that forced a patient to drop would-be blockbuster Hemlibra
Endpoints
Roche
hemophilia
Hemlibra
anti-drug antibodies
Flag link:
Roche gets double dose of good Hemlibra news with FDA breakthrough, ICER backing
Roche gets double dose of good Hemlibra news with FDA breakthrough, ICER backing
Fierce Pharma
Roche
Hemlibra
hemophilia
FDA
breakthrough status
ICER
Flag link:
Novo charts course for sickle cell amid headwinds in hemophilia
Novo charts course for sickle cell amid headwinds in hemophilia
Biopharma Dive
Novo Nordisk
sickle cell disease
hemophilia
EPI01
EpiDestiny
Flag link:
Under fire for 5 deaths of patients taking Hemlibra, Roche spills details
Under fire for 5 deaths of patients taking Hemlibra, Roche spills details
Fierce Pharma
Hemlibra
Roche
hemophilia
Flag link:
Hemophilia groups warned of 5 deaths among patients taking Roche’s big new blockbuster Hemlibra
Hemophilia groups warned of 5 deaths among patients taking Roche’s big new blockbuster Hemlibra
Endpoints
hemophilia
Roche
Hemlibra
Flag link:
Sanofi Leads the Hemophilia Space on Bioverativ Acquisition
Sanofi Leads the Hemophilia Space on Bioverativ Acquisition
Market Realist
Sanofi
hemophilia
Bioverativ
M&A
Flag link:
Sanofi to Buy Biogen Hemophilia Spinoff for $11.6 Billion
Sanofi to Buy Biogen Hemophilia Spinoff for $11.6 Billion
Bloomberg
Sanofi
M&A
Bioverativ
Biogen
hemophilia
Flag link:
Shire's latest approval won't save it from Hemlibra
Shire's latest approval won't save it from Hemlibra
Biopharma Dive
Shire
Hemlibra
Adynovi
hemophilia
Europe
Adynovate
Flag link:
Shire looks to stall Hemlibra impact with court injunction
Shire looks to stall Hemlibra impact with court injunction
BioPharma Dive
Shire
Hemlibra
Roche
hemophilia
Flag link:
Alnylam, Sanofi given the all-clear to resume fitusiran trials
Alnylam, Sanofi given the all-clear to resume fitusiran trials
BioPharma Dive
Alnylam
Sanofi
clinical trials
fitusiran
hemophilia
Flag link:
Shire CEO: Hemophilia will remain a core business
Shire CEO: Hemophilia will remain a core business
BioPharma Dive
Shire
Pharma CEOs
hemophilia
Flemming Ornskov
Flag link:
Disruption of the Year: Long-Acting Hemophilia Drugs
Disruption of the Year: Long-Acting Hemophilia Drugs
BioPharma Dive
hemophilia
Eloctate
Kovaltry
Bayer
Bioverativ
Flag link:

Pages